A Phase 2, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of belimumab and rituximab co-administration in subjects with primary Sjögren's syndrome A Phase 2, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of ...
A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subjects with primary Sjögren's syndrome. - NA A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and ...